Endometriosis Treatment Market

Endometriosis Treatment Market By Drug (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, LNR-IUDs), Treatment Type (Hormonal Therapy, Pain Management), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, e-Commerce) & Region - Forecast 2019 - 2030

Market Insights on Endometriosis Treatment covering sales outlook, demand forecast and up-to-date key trends

Request Sample

Oral Contraceptive Drugs Capture Around 50% Value Share

Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions. However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.

By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Opportunities Prevail in Developed Regions

Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross US$ 1 Bn in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.

Endometriosis Treatment Market

While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.

Advanced Drug Delivery Technologies to Propel Market Growth

Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.

Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How Growth will Unfold

Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals prefer hormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.

Endometriosis Treatment Market

That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

Oral Contraceptives
Progestins
NSAIDs
GnRH Analogues
LNR-IUDs
Others

Treatment Type:

Hormonal Therapy
Pain Management

Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drugstores
e-Commerce

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

Frequently Asked Questions

What is the Growth Outlook for Endometriosis Treatment Market?

The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.

By 2032, how much can the Endometriosis Treatment Market Grow?

The endometriosis treatment market size is estimated to cross US$ 3.55 Billion by 2032.

What is the Current Valuation of the Endometriosis Treatment Market?

The endometriosis treatment market is likely to record a value of US$ 1.30 Billion in 2022.

Which Region is likely to Lead the Endometriosis Treatment Market?

Europe is likely to lead the endometriosis treatment market.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Drug Development Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis

4.2. Endometriosis Epidemiology, By Key Region

4.3. Unmet Needs of Endometriosis Treatment

4.3.1. Potential Diagnostic Biomarkers for Endometriosis

4.3.1.1. Existing & Emerging Non-invasive Diagnostics Techniques

4.3.2. Disease Awareness and Educational Strategies for Medical Professionals

4.3.3. Drug Effectivity & Safety, By Drug

4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis

4.3.5. Disease Etiology and Pathophysiology

4.4. Research and Development Strategies

4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs

4.4.2. Pipeline Assessment of GnRH Antagonists

4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies

4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies)

4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication)

4.5. Attributes/Factors Important in Clinical Trials

4.6. Clinical Trial History of Key Marketed Drugs

4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs

4.8. Pipeline Assessment/Clinical Benchmark Analysis

4.8.1. Marketed Drug/Pipeline Valuation Analysis

4.8.1.1. Therapeutic Advantages by Drug

4.8.1.2. New Drug Launches and Regulatory Approvals, 2019-2030

4.8.1.3. Opportunity Assessment in terms of Revenue, 2020-2025

4.8.1.4. Clinical Trials and Pipeline Overview

4.9. Regulatory Scenario

4.10. Reimbursement Scenario

4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities

5. Global Market Demand (Size in US$ Mn) Analysis 2014-2018 and Opportunity Assessment, 2019-2030

5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018

5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2030

5.2.1. Y-o-Y Growth Trend Analysis

5.2.2. Absolute $ Opportunity Analysis

6. Market Background

6.1. Macro-Economic Factors

6.1.1. Global GDP Growth Outlook

6.1.2. Global Healthcare Outlook

6.1.3. Per Capita Healthcare Expenditure Outlook

6.2. Opportunity Assessment Factors - Relevance & Impact

6.2.1. Prevalence of Endometriosis

6.2.2. Growing Healthcare Expenditure

6.2.3. Increasing Number of Clinical Trials

6.2.4. Regulatory Policy Changes

6.3. Market Dynamics

6.3.1. Drivers

6.3.2. Restraints

6.3.3. Opportunity Analysis

7. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Drug

7.1. Introduction / Key Findings

7.2. Historical Market Size (US$ Mn) Analysis By Drug, 2014-2018

7.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Drug, 2019-2030

7.3.1. Oral Contraceptives

7.3.2. Progestins

7.3.3. NSAIDs

7.3.4. GnRH Analogues

7.3.5. LNR-IUDs

7.3.6. Others

7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Treatment Type

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014-2018

8.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Treatment Type, 2019-2030

8.3.1. Hormonal Therapy

8.3.2. Pain management

8.4. Market Attractiveness Analysis By Treatment Type

9. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Distribution Channel

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014-2018

9.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Distribution Channel, 2019-2030

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Drugstores

9.3.4. E-commerce

9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Region

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018

10.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Region, 2019-2030

10.3.1. North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. East Asia

10.3.5. South Asia

10.3.6. Oceania

10.3.7. Middle East and Africa (MEA)

10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

11.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

11.3.1. By Country

11.3.1.1. U.S.

11.3.1.2. Canada

11.3.2. By Drug

11.3.3. By Treatment Type

11.3.4. By Distribution Channel

11.4. Market Attractiveness Analysis

11.4.1. By Country

11.4.2. By Drug

11.4.3. By Treatment Type

11.4.4. By Distribution Channel

11.5. Key Market Participants - Intensity Mapping

11.6. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

12.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

12.3.1. By Country

12.3.1.1. Brazil

12.3.1.2. Mexico

12.3.1.3. Argentina

12.3.1.4. Rest of Latin America

12.3.2. By Drug

12.3.3. By Treatment Type

12.3.4. By Distribution Channel

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Drug

12.4.3. By Treatment Type

12.4.4. By Distribution Channel

12.5. Key Market Participants - Intensity Mapping

12.6. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

13.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

13.3.1. By Country

13.3.1.1. Germany

13.3.1.2. Italy

13.3.1.3. France

13.3.1.4. U.K.

13.3.1.5. Spain

13.3.1.6. BENELUX

13.3.1.7. Russia

13.3.1.8. Rest of Europe

13.3.2. By Drug

13.3.3. By Treatment Type

13.3.4. By Distribution Channel

13.4. Market Attractiveness Analysis

13.4.1. By Country

13.4.2. By Drug

13.4.3. By Treatment Type

13.4.4. By Distribution Channel

13.5. Key Market Participants - Intensity Mapping

13.6. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

14.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

14.3.1. By Country

14.3.1.1. India

14.3.1.2. Thailand

14.3.1.3. Indonesia

14.3.1.4. Malaysia

14.3.1.5. Rest of South Asia

14.3.2. By Drug

14.3.3. By Treatment Type

14.3.4. By Distribution Channel

14.4. Market Attractiveness Analysis

14.4.1. By Country

14.4.2. By Drug

14.4.3. By Treatment Type

14.4.4. By Distribution Channel

14.5. Key Market Participants - Intensity Mapping

14.6. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

15.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

15.3.1. By Country

15.3.1.1. China

15.3.1.2. Japan

15.3.1.3. South Korea

15.3.2. By Drug

15.3.3. By Treatment Type

15.3.4. By Distribution Channel

15.4. Market Attractiveness Analysis

15.4.1. By Country

15.4.2. By Drug

15.4.3. By Treatment Type

15.4.4. By Distribution Channel

15.5. Key Market Participants - Intensity Mapping

15.6. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

16.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

16.3.1. By Country

16.3.1.1. Australia

16.3.1.2. New Zealand

16.3.2. By Drug

16.3.3. By Treatment Type

16.3.4. By Distribution Channel

16.4. Market Attractiveness Analysis

16.4.1. By Country

16.4.2. By Drug

16.4.3. By Treatment Type

16.4.4. By Distribution Channel

16.5. Key Market Participants - Intensity Mapping

16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

17.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

17.3.1. By Country

17.3.1.1. GCC Countries

17.3.1.2. Turkey

17.3.1.3. Northern Africa

17.3.1.4. South Africa

17.3.1.5. Rest of Middle East and Africa

17.3.2. By Drug

17.3.3. By Treatment Type

17.3.4. By Distribution Channel

17.4. Market Attractiveness Analysis

17.4.1. By Country

17.4.2. By Drug

17.4.3. By Treatment Type

17.4.4. By Distribution Channel

17.5. Key Market Participants - Intensity Mapping

17.6. Drivers and Restraints - Impact Analysis

18. Emerging Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

18.1. Introduction

18.1.1. Market Value Proportion Analysis, By Key Countries

18.1.2. Global Vs. Country Growth Comparison

18.2. India Market Analysis

18.2.1. Introduction

18.2.2. PEST Analysis

18.2.3. Market Value Analysis by Market Taxonomy

18.2.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

18.2.4.1. By Drug

18.2.4.2. By Treatment Type

18.2.4.3. By Distribution Channel

18.3. China Market Analysis

18.3.1. Introduction

18.3.2. PEST Analysis

18.3.3. Market Value Analysis by Market Taxonomy

18.3.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

18.3.4.1. Drug

18.3.4.2. By Treatment Type

18.3.4.3. By Distribution Channel

18.4. Brazil Market Analysis

18.4.1. Introduction

18.4.2. PEST Analysis

18.4.3. Market Value Analysis by Market Taxonomy

18.4.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

18.4.4.1. By Drug

18.4.4.2. By Treatment Type

18.4.4.3. By Distribution Channel

19. U.S. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

19.1. Introduction

19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

19.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

19.3.1. By Drug

19.3.2. By Treatment Type

19.3.3. By Distribution Channel

19.4. Market Attractiveness Analysis

20. Canada Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

20.1. Introduction

20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

20.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

20.3.1. By Drug

20.3.2. By Treatment Type

20.3.3. By Distribution Channel

20.4. Market Attractiveness Analysis

21. Mexico Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

21.1. Introduction

21.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

21.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

21.3.1. By Drug

21.3.2. By Treatment Type

21.3.3. By Distribution Channel

21.4. Market Attractiveness Analysis

22. Germany Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

22.1. Introduction

22.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

22.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

22.3.1. By Drug

22.3.2. By Treatment Type

22.3.3. By Distribution Channel

22.4. Market Attractiveness Analysis

23. U.K. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

23.1. Introduction

23.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

23.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

23.3.1. By Drug

23.3.2. By Treatment Type

23.3.3. By Distribution Channel

23.4. Market Attractiveness Analysis

24. France Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

24.1. Introduction

24.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

24.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

24.3.1. By Drug

24.3.2. By Treatment Type

24.3.3. By Distribution Channel

24.4. Market Attractiveness Analysis

25. Italy Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

25.1. Introduction

25.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

25.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

25.3.1. By Drug

25.3.2. By Treatment Type

25.3.3. By Distribution Channel

25.4. Market Attractiveness Analysis

26. Spain Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

26.1. Introduction

26.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

26.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

26.3.1. By Drug

26.3.2. By Treatment Type

26.3.3. By Distribution Channel

26.4. Market Attractiveness Analysis

27. Russia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

27.1. Introduction

27.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

27.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

27.3.1. By Drug

27.3.2. By Treatment Type

27.3.3. By Distribution Channel

27.4. Market Attractiveness Analysis

27.5. Market Attractiveness Analysis

28. Japan Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

28.1. Introduction

28.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

28.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

28.3.1. By Drug

28.3.2. By Treatment Type

28.3.3. By Distribution Channel

28.4. Market Attractiveness Analysis

29. South Korea Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

29.1. Introduction

29.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

29.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

29.3.1. By Drug

29.3.2. By Treatment Type

29.3.3. By Distribution Channel

29.4. Market Attractiveness Analysis

30. Australia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

30.1. Introduction

30.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

30.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

30.3.1. By Drug

30.3.2. By Treatment Type

30.3.3. By Distribution Channel

30.4. Market Attractiveness Analysis

31. New Zealand Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

31.1. Introduction

31.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

31.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

31.3.1. By Drug

31.3.2. By Treatment Type

31.3.3. By Distribution Channel

31.4. Market Attractiveness Analysis

32. GCC Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

32.1. Introduction

32.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

32.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

32.3.1. By Drug

32.3.2. By Treatment Type

32.3.3. By Distribution Channel

32.4. Market Attractiveness Analysis

33. South Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

33.1. Introduction

33.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

33.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

33.3.1. By Drug

33.3.2. By Treatment Type

33.3.3. By Distribution Channel

33.4. Market Attractiveness Analysis

34. Market Structure Analysis

34.1. Market Analysis by Tier of Companies

34.2. Market Share Analysis of Top Players

34.3. Company Share Analysis

34.4. Market Presence Analysis

34.4.1. By Regional footprint of Players

34.4.2. Channel Foot Print by Players

35. Competition Analysis

35.1. Competition Dashboard

35.2. Competition Benchmarking

35.3. Competition Deep Dive (Tentative List)

35.3.1. AbbVie Inc.

35.3.1.1. Overview

35.3.1.2. Service Portfolio

35.3.1.3. Profitability by Market Segments (Service/Channel/Region)

35.3.1.4. Sales Footprint

35.3.1.5. Strategy Overview

35.3.1.5.1. Marketing Strategy

35.3.1.5.2. Service Strategy

35.3.1.5.3. Channel Strategy

35.3.2. Bayer AG

35.3.2.1. Overview

35.3.2.2. Service Portfolio

35.3.2.3. Profitability by Market Segments (Service/Channel/Region)

35.3.2.4. Sales Footprint

35.3.2.5. Strategy Overview

35.3.2.5.1. Marketing Strategy

35.3.2.5.2. Service Strategy

35.3.2.5.3. Channel Strategy

35.3.3. AstraZeneca

35.3.3.1. Overview

35.3.3.2. Service Portfolio

35.3.3.3. Profitability by Market Segments (Service/Channel/Region)

35.3.3.4. Sales Footprint

35.3.3.5. Strategy Overview

35.3.3.5.1. Marketing Strategy

35.3.3.5.2. Service Strategy

35.3.3.5.3. Channel Strategy

35.3.4. Pfizer Inc.

35.3.4.1. Overview

35.3.4.2. Service Portfolio

35.3.4.3. Profitability by Market Segments (Service/Channel/Region)

35.3.4.4. Sales Footprint

35.3.4.5. Strategy Overview

35.3.4.5.1. Marketing Strategy

35.3.4.5.2. Service Strategy

35.3.4.5.3. Channel Strategy

35.3.5. Teva Pharmaceutical Industries Ltd.

35.3.5.1. Overview

35.3.5.2. Service Portfolio

35.3.5.3. Profitability by Market Segments (Service/Channel/Region)

35.3.5.4. Sales Footprint

35.3.5.5. Strategy Overview

35.3.5.5.1. Marketing Strategy

35.3.5.5.2. Service Strategy

35.3.5.5.3. Channel Strategy

35.3.6. Ipsen Pharma

35.3.6.1. Overview

35.3.6.2. Service Portfolio

35.3.6.3. Profitability by Market Segments (Service/Channel/Region)

35.3.6.4. Sales Footprint

35.3.6.5. Strategy Overview

35.3.6.5.1. Marketing Strategy

35.3.6.5.2. Service Strategy

35.3.6.5.3. Channel Strategy

35.3.7. Myovant Sciences

35.3.7.1. Overview

35.3.7.2. Service Portfolio

35.3.7.3. Profitability by Market Segments (Service/Channel/Region)

35.3.7.4. Sales Footprint

35.3.7.5. Strategy Overview

35.3.7.5.1. Marketing Strategy

35.3.7.5.2. Service Strategy

35.3.7.5.3. Channel Strategy

35.3.8. Endoceutics, Inc.

35.3.8.1. Overview

35.3.8.2. Service Portfolio

35.3.8.3. Profitability by Market Segments (Service/Channel/Region)

35.3.8.4. Sales Footprint

35.3.8.5. Strategy Overview

35.3.8.5.1. Marketing Strategy

35.3.8.5.2. Service Strategy

35.3.8.5.3. Channel Strategy

35.3.9. Debiopharm Group

35.3.9.1. Overview

35.3.9.2. Service Portfolio

35.3.9.3. Profitability by Market Segments (Service/Channel/Region)

35.3.9.4. Sales Footprint

35.3.9.5. Strategy Overview

35.3.9.5.1. Marketing Strategy

35.3.9.5.2. Service Strategy

35.3.9.5.3. Channel Strategy

35.3.10. Mayne Pharma Group Limited

35.3.10.1. Overview

35.3.10.2. Service Portfolio

35.3.10.3. Profitability by Market Segments (Service/Channel/Region)

35.3.10.4. Sales Footprint

35.3.10.5. Strategy Overview

35.3.10.5.1. Marketing Strategy

35.3.10.5.2. Service Strategy

35.3.10.5.3. Channel Strategy

35.3.11. Noven Pharmaceuticals, Inc.

35.3.11.1. Overview

35.3.11.2. Service Portfolio

35.3.11.3. Profitability by Market Segments (Service/Channel/Region)

35.3.11.4. Sales Footprint

35.3.11.5. Strategy Overview

35.3.11.5.1. Marketing Strategy

35.3.11.5.2. Service Strategy

35.3.11.5.3. Channel Strategy

35.3.12. Sun Pharmaceutical Industries Limited

35.3.12.1. Overview

35.3.12.2. Service Portfolio

35.3.12.3. Profitability by Market Segments (Service/Channel/Region)

35.3.12.4. Sales Footprint

35.3.12.5. Strategy Overview

35.3.12.5.1. Marketing Strategy

35.3.12.5.2. Service Strategy

35.3.12.5.3. Channel Strategy

35.3.13. Amneal Pharmaceuticals, Inc. Market_Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2030

35.3.13.1. Overview

35.3.13.2. Service Portfolio

35.3.13.3. Profitability by Market Segments (Service/Channel/Region)

35.3.13.4. Sales Footprint

35.3.13.5. Strategy Overview

35.3.13.5.1. Marketing Strategy

35.3.13.5.2. Service Strategy

35.3.13.5.3. Channel Strategy

35.3.14. Mylan N.V.

35.3.14.1. Overview

35.3.14.2. Service Portfolio

35.3.14.3. Profitability by Market Segments (Service/Channel/Region)

35.3.14.4. Sales Footprint

35.3.14.5. Strategy Overview

35.3.14.5.1. Marketing Strategy

35.3.14.5.2. Service Strategy

35.3.14.5.3. Channel Strategy

35.3.15. Aurobindo Pharma

35.3.15.1. Overview

35.3.15.2. Service Portfolio

35.3.15.3. Profitability by Market Segments (Service/Channel/Region)

35.3.15.4. Sales Footprint

35.3.15.5. Strategy Overview

35.3.15.5.1. Marketing Strategy

35.3.15.5.2. Service Strategy

35.3.15.5.3. Channel Strategy

36. Assumptions and Acronyms Used

37. Research Methodology

List of Tables

Table 01: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2014-2030, By Drug

Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2014-2030, By Treatment Type 

Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2014-2030, By Distribution Channel

Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2014-2030, By Region 

Table 05: North America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 06: North America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 07: North America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 08: North America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 09: Latin America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 10: Latin America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 11: Latin America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 12: Latin America Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 13: Europe Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 14: Europe Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 15: Europe Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 16: Europe Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 17: South Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 18: South Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 19: South Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 20: South Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 21: East Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 22: East Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 23: East Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 24: East Asia Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 25: Oceania Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 26: Oceania Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 27: Oceania Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 28: Oceania Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 29: MEA Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Country

Table 30: MEA Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 31: MEA Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 32: MEA Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channel

Table 33: India Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 34: India Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 35: India Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channels

Table 36: China Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 37: China Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 38: China Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channels

Table 39: Brazil Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Drug

Table 40: Brazil Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Treatment Type

Table 41: Brazil Market Value (US$ Mn) Analysis 2014-2018 and Forecast 2019-2030, By Distribution Channels

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 01: Global Market Value Analysis (US$ Mn), 2014-2018

Figure 02: Global Market Value Forecast (US$ Mn), 2019-2030

Figure 03: Global Market Absolute $ Opportunity, 2019 - 2030

Figure 04: Global Market Share Analysis (%), By Drug, 2019-2030

Figure 05: Global Market Y-o-Y Analysis (%), By Drug, 2019-2030

Figure 06: Global Market Attractiveness Analysis by Drug, 2019-2030

Figure 07: Global Market Share Analysis (%), By Treatment Type, 2019-2030

Figure 08: Global Market Y-o-Y Analysis (%), By Treatment Type, 2019-2030

Figure 09: Global Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 10: Global Market Share Analysis (%), By Distribution Channel, 2019-2030

Figure 11: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2019-2030

Figure 12: Global Market Attractiveness Analysis by Distribution Channel, 2019-2030

Figure 13: Global Market Share Analysis (%), By Region, 2019-2030

Figure 14: Global Market Y-o-Y Analysis (%), By Region, 2019-2030

Figure 15: Global Market Attractiveness Analysis by Region, 2019-2030

Figure 16: North America Market Value Share, By Drug, 2019 (E)

Figure 17: North America Market Value Share, By Treatment Type, 2019 (E)

Figure 18: North America Market Value Share, By Distribution Channel, 2019 (E)

Figure 19: North America Market Value Share, By Country, 2019 (E)

Figure 20: North America Market Value Analysis (US$ Mn), 2014-2018

Figure 21: North America Market Value Forecast (US$ Mn), 2019-2030

Figure 22: North America Market Attractiveness Analysis by Drug, 2019-2030

Figure 23: North America Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 24: North America Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 25: North America Market Attractiveness Analysis by Country, 2019-2030

Figure 26: Latin America Market Value Share, By Drug, 2019 (E)

Figure 27: Latin America Market Value Share, By Treatment Type, 2019 (E)

Figure 28: Latin America Market Value Share, By Distribution Channel, 2019 (E)

Figure 29: Latin America Market Value Share, By Country, 2019 (E)

Figure 30: Latin America Market Value Analysis (US$ Mn), 2014-2018

Figure 31: Latin America Market Value Forecast (US$ Mn), 2019-2030

Figure 32: Latin America Market Attractiveness Analysis by Drug, 2019-2030

Figure 33: Latin America Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 34: Latin America Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 35: Latin America Market Attractiveness Analysis by Country, 2019-2030

Figure 36: Europe Market Value Share, By Drug, 2019 (E)

Figure 37: Europe Market Value Share, By Treatment Type, 2019 (E)

Figure 38: Europe Market Value Share, By Distribution Channel, 2019 (E)

Figure 39: Europe Market Value Share, By Country, 2019 (E)

Figure 40: Europe Market Value Analysis (US$ Mn), 2014-2018

Figure 41: Europe Market Value Forecast (US$ Mn), 2019-2030

Figure 42: Europe Market Attractiveness Analysis by Drug, 2019-2030

Figure 43: Europe Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 44: Europe Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 45: Europe Market Attractiveness Analysis by Country, 2019-2030

Figure 46: South Asia Market Value Share, By Drug, 2019 (E)

Figure 47: South Asia Market Value Share, By Treatment Type, 2019 (E)

Figure 48: South Asia Market Value Share, By Distribution Channel, 2019 (E)

Figure 49: South Asia Market Value Share, By Country, 2019 (E)

Figure 50: South Asia Market Value Analysis (US$ Mn), 2014-2018

Figure 51: South Asia Market Value Forecast (US$ Mn), 2019-2030

Figure 52: South Asia Market Attractiveness Analysis by Drug, 2019-2030

Figure 53: South Asia Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 54: South Asia Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 55: South Asia Market Attractiveness Analysis by Country, 2019-2030

Figure 56: East Asia Market Value Share, By Drug, 2019 (E)

Figure 57: East Asia Market Value Share, By Treatment Type, 2019 (E)

Figure 58: East Asia Market Value Share, By Distribution Channel, 2019 (E)

Figure 59: East Asia Market Value Share, By Country, 2019 (E)

Figure 60: East Asia Market Value Analysis (US$ Mn), 2014-2018

Figure 61: East Asia Market Value Forecast (US$ Mn), 2019-2030

Figure 62: East Asia Market Attractiveness Analysis by Drug, 2019-2030

Figure 63: East Asia Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 64: East Asia Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 65: East Asia Market Attractiveness Analysis by Country, 2019-2030

Figure 66: Oceania Market Value Share, By Drug, 2019 (E)

Figure 67: Oceania Market Value Share, By Treatment Type, 2019 (E)

Figure 68: Oceania Market Value Share, By Distribution Channel, 2019 (E)

Figure 69: Oceania Market Value Share, By Country, 2019 (E)

Figure 70: Oceania Market Value Analysis (US$ Mn), 2014-2018

Figure 71: Oceania Market Value Forecast (US$ Mn), 2019-2030

Figure 72: Oceania Market Attractiveness Analysis by Drug, 2019-2030

Figure 73: Oceania Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 74: Oceania Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 75: Oceania Market Attractiveness Analysis by Country, 2019-2030

Figure 76: MEA Market Value Share, By Drug, 2019 (E)

Figure 77: MEA Market Value Share, By Treatment Type, 2019 (E)

Figure 78: MEA Market Value Share, By Distribution Channel, 2019 (E)

Figure 79: MEA Market Value Share, By Country, 2019 (E)

Figure 80: MEA Market Value Analysis (US$ Mn), 2014-2018

Figure 81: MEA Market Value Forecast (US$ Mn), 2019-2030

Figure 82: MEA Market Attractiveness Analysis by Drug, 2019-2030

Figure 83: MEA Market Attractiveness Analysis by Treatment Type, 2019-2030

Figure 84: MEA Market Attractiveness Analysis by Distribution Channels, 2019-2030

Figure 85: MEA Market Attractiveness Analysis by Country, 2019-2030

Figure 86: India Market Value Analysis (US$ Mn), 2014-2018

Figure 87: India Market Value Forecast (US$ Mn), 2019-2030

Figure 88: China Market Value Analysis (US$ Mn), 2014-2018

Figure 89: China Market Value Forecast (US$ Mn), 2019-2030

Figure 90: Brazil Market Value Analysis (US$ Mn), 2014-2018

Figure 91: Brazil Market Value Forecast (US$ Mn), 2019-2030

Figure 92: U. S. Market Value Analysis (US$ Mn), 2019 & 2030

Figure 93: U. S. Market Value Share, By Drug, 2019 (E)

Figure 94: U. S. Market Value Share, By Treatment Type, 2019 (E)

Figure 95: U. S. Market Value Share, By Distribution Channel, 2019 (E)

Figure 96: Canada Market Value Analysis (US$ Mn), 2019 & 2030

Figure 97: Canada Market Value Share, By Drug, 2019 (E)

Figure 98: Canada Market Value Share, By Treatment Type, 2019 (E)

Figure 99: Canada Market Value Share, By Distribution Channel, 2019 (E)

Figure 100: Mexico Market Value Analysis (US$ Mn), 2019 & 2030

Figure 101: Mexico Market Value Share, By Drug, 2019 (E)

Figure 102: Mexico Market Value Share, By Treatment Type, 2019 (E)

Figure 103: Mexico Market Value Share, By Distribution Channel, 2019 (E)

Figure 104: Germany Market Value Analysis (US$ Mn), 2019 & 2030

Figure 105: Germany Market Value Share, By Drug, 2019 (E)

Figure 106: Germany Market Value Share, By Treatment Type, 2019 (E)

Figure 107: Germany Market Value Share, By Distribution Channel, 2019 (E)

Figure 108: U.K. Market Value Analysis (US$ Mn), 2019 & 2030

Figure 109: U.K. Market Value Share, By Drug, 2019 (E)

Figure 110: U.K Market Value Share, By Treatment Type, 2019 (E)

Figure 111: U.K. Market Value Share, By Distribution Channel, 2019 (E)

Figure 112: France Market Value Analysis (US$ Mn), 2019 & 2030

Figure 113: France Market Value Share, By Drug, 2019 (E)

Figure 114: France Market Value Share, By Treatment Type, 2019 (E)

Figure 115: France Market Value Share, By Distribution Channel, 2019 (E)

Figure 116: Italy Market Value Analysis (US$ Mn), 2019 & 2030

Figure 117: Italy Market Value Share, By Drug, 2019 (E)

Figure 118: Italy Market Value Share, By Treatment Type, 2019 (E)

Figure 119: Italy Market Value Share, By Distribution Channel, 2019 (E)

Figure 120: Spain Market Value Analysis (US$ Mn), 2019 & 2030

Figure 121: Spain Market Value Share, By Drug, 2019 (E)

Figure 122: Spain Market Value Share, By Treatment Type, 2019 (E)

Figure 123: Spain Market Value Share, By Distribution Channel, 2019 (E)

Figure 124: Russia Market Value Analysis (US$ Mn), 2019 & 2030

Figure 125: Russia Market Value Share, By Drug, 2019 (E)

Figure 126: Russia Market Value Share, By Treatment Type, 2019 (E)

Figure 127: Russia Market Value Share, By Distribution Channel, 2019 (E)

Figure 128: Japan Market Value Analysis (US$ Mn), 2019 & 2030

Figure 129: Japan Market Value Share, By Drug, 2019 (E)

Figure 130: Japan Market Value Share, By Treatment Type, 2019 (E)

Figure 131: Japan Market Value Share, By Distribution Channel, 2019 (E)

Figure 132: South Korea Market Value Analysis (US$ Mn), 2019 & 2030

Figure 133: South Korea Market Value Share, By Drug, 2019 (E)

Figure 134: South Korea Market Value Share, By Treatment Type, 2019 (E)

Figure 135: South Korea Market Value Share, By Distribution Channel, 2019 (E)

Figure 136: Australia Market Value Analysis (US$ Mn), 2019 & 2030

Figure 137: Australia Market Value Share, By Drug, 2019 (E)

Figure 138: Australia Market Value Share, By Treatment Type, 2019 (E)

Figure 139: Australia Market Value Share, By Distribution Channel, 2019 (E)

Figure 140: New Zealand Market Value Analysis (US$ Mn), 2019 & 2030

Figure 141: New Zealand Market Value Share, By Drug, 2019 (E)

Figure 142: New Zealand Market Value Share, By Treatment Type, 2019 (E)

Figure 143: New Zealand Market Value Share, By Distribution Channel, 2019 (E)

Figure 144: GCC Countries Market Value Analysis (US$ Mn), 2019 & 2030

Figure 145: GCC Countries Market Value Share, By Drug, 2019 (E)

Figure 146: GCC Countries Market Value Share, By Treatment Type, 2019 (E)

Figure 147: GCC Countries Market Value Share, By Distribution Channel, 2019 (E)

Figure 148: South Africa Market Value Analysis (US$ Mn), 2019 & 2030

Figure 149: South Africa Market Value Share, By Drug, 2019 (E)

Figure 150: South Africa Market Value Share, By Treatment Type, 2019 (E)

Figure 151: South Africa Market Value Share, By Distribution Channel, 2019 (E)

Figure 152: Turkey Market Value Analysis (US$ Mn), 2019 & 2030

Figure 153: Turkey Market Value Share, By Drug, 2019 (E)

Figure 154: Turkey Market Value Share, By Treatment Type, 2019 (E)

Figure 155: Turkey Market Value Share, By Distribution Channel, 2019 (E)